Inogen Inc ( (INGN) ) has released its Q4 earnings. Here is a breakdown of the information Inogen Inc presented to its investors.
Inogen, Inc. is a leading global medical technology company specializing in innovative respiratory products for homecare settings, supporting patients with chronic respiratory conditions through advanced therapy devices.
Inogen has reported a strong financial performance for the fourth quarter and full year of 2024, with notable revenue growth and strategic advancements. The company achieved a 5.5% increase in fourth-quarter revenue and a 6.4% rise for the full year, driven by increased demand and new international and domestic business-to-business sales.
Key financial highlights include a significant improvement in gross margin to 45.3% in the fourth quarter and 46.1% for the year, attributed to lower raw material costs and operational efficiencies. The company also reduced its operating loss to $11.4 million in Q4 and $42.5 million for the year, compared to higher losses in 2023. Additionally, Inogen’s strategic collaboration with Yuwell aims to expand its product portfolio and global reach.
Looking ahead, Inogen anticipates continued growth in 2025, with projected revenue increases of 1% to 4% for the first quarter and 5% to 6% for the full year. The company remains focused on enhancing profitability and leveraging its strategic partnerships to drive sustained success.